Key result
Slow titration clozapine rechallenge succeeds without myocarditis recurrence over 36 months after a prior episode.
Why the study?
Clozapine is effective for treatment-resistant schizophrenia but its use is limited by life-threatening side effects such as myocarditis.
Does clozapine rechallenge cause recurrent myocarditis in a patient with a history of clozapine-induced myocarditis?
Case Report (n=1)
No
Does clozapine rechallenge cause recurrent myocarditis in a patient with a history of clozapine-induced myocarditis?
Successful rechallenge of clozapine in a patient with prior clozapine-induced myocarditis suggests it may be a viable option for select patients with treatment-resistant schizophrenia.
Answers are grounded in this paper and cite their sources.
May support cautious clozapine rechallenge in refractory schizophrenia after myocarditis; leaves open need for prospective safety data.
Clozapine is the only antipsychotic with proven efficacy in treatment-resistant schizophrenia, but some life-threatening side effects limit its use.Here we report a patient with clozapine-induced myocarditis and successful rechallenge.The patient still uses clozapine and has not developed myocarditis over 36 months of observation.It may be possible to use clozapine even after myocarditis and thus improve symptoms and functionality of schizophrenia patients.
No takes yet. Share an insight, caveat, or question.
Buket Koparal (2020) conducted a case report in Treatment-resistant schizophrenia and clozapine-induced myocarditis (n=1). Clozapine rechallenge was evaluated on Recurrence of myocarditis or cardiac side effects. A slow titration rechallenge of clozapine in a patient with prior clozapine-induced myocarditis was successful, with no recurrence of cardiac side effects over 36 months.
Synapse has enriched 10 related papers. Consider them for comparative context: